CONTEXT: PCSK9 is a secreted protein that influences plasma levels of low-density lipoprotein cholesterol (LDL-C) and susceptibility to coronary heart disease. PCSK9 is present in human plasma, but the factors that contribute to differences in plasma concentrations of PCSK9 and how they impact on the levels of lipoproteins have not been well-characterized. OBJECTIVE: The aim of the study was to measure PCSK9 levels in a large, ethnically diverse population (n = 3138) utilizing a sensitive and specific sandwich ELISA. DESIGN: We conducted an observational study in the Dallas Heart Study, a multiethnic, probability-based sample of Dallas County. RESULTS: Plasma levels of PCSK9 varied over approximately 100-fold range (33-2988 ng/ml; median, 487 ng/ml). Levels were significantly higher in women (517 ng/ml) than in men (450 ng/ml), and in postmenopausal women compared to premenopausal women (P < 0.0001), irrespective of estrogen status. Plasma levels of PCSK9 correlated with plasma levels of LDL-C (r = 0.24) but explained less than 8% of the variation in LDL-C levels (r(2) = 0.073). Other factors that correlated with PCSK9 levels included plasma levels of triglycerides, insulin, and glucose. Individuals with loss-of-function mutations in PCSK9 and reduced plasma levels of LDL-C also had significantly lower plasma levels of PCSK9 after adjusting for age, gender, and LDL-C levels (P < 0.0001). CONCLUSION: Multiple metabolic and genetic factors contribute to variation in plasma levels of PCSK9 in the general population. Although levels of PCSK9 correlate with plasma levels of LDL-C, they account for only a small proportion of the variation in the levels of this lipoprotein.
CONTEXT: PCSK9 is a secreted protein that influences plasma levels of low-density lipoprotein cholesterol (LDL-C) and susceptibility to coronary heart disease. PCSK9 is present in human plasma, but the factors that contribute to differences in plasma concentrations of PCSK9 and how they impact on the levels of lipoproteins have not been well-characterized. OBJECTIVE: The aim of the study was to measure PCSK9 levels in a large, ethnically diverse population (n = 3138) utilizing a sensitive and specific sandwich ELISA. DESIGN: We conducted an observational study in the Dallas Heart Study, a multiethnic, probability-based sample of Dallas County. RESULTS: Plasma levels of PCSK9 varied over approximately 100-fold range (33-2988 ng/ml; median, 487 ng/ml). Levels were significantly higher in women (517 ng/ml) than in men (450 ng/ml), and in postmenopausal women compared to premenopausal women (P < 0.0001), irrespective of estrogen status. Plasma levels of PCSK9 correlated with plasma levels of LDL-C (r = 0.24) but explained less than 8% of the variation in LDL-C levels (r(2) = 0.073). Other factors that correlated with PCSK9 levels included plasma levels of triglycerides, insulin, and glucose. Individuals with loss-of-function mutations in PCSK9 and reduced plasma levels of LDL-C also had significantly lower plasma levels of PCSK9 after adjusting for age, gender, and LDL-C levels (P < 0.0001). CONCLUSION: Multiple metabolic and genetic factors contribute to variation in plasma levels of PCSK9 in the general population. Although levels of PCSK9 correlate with plasma levels of LDL-C, they account for only a small proportion of the variation in the levels of this lipoprotein.
Authors: Jonathan Cohen; Alexander Pertsemlidis; Ingrid K Kotowski; Randall Graham; Christine Kim Garcia; Helen H Hobbs Journal: Nat Genet Date: 2005-01-16 Impact factor: 38.330
Authors: Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton Journal: Proc Natl Acad Sci U S A Date: 2005-04-01 Impact factor: 11.205
Authors: Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs Journal: Hepatology Date: 2004-12 Impact factor: 17.425
Authors: Jay D Horton; Nila A Shah; Janet A Warrington; Norma N Anderson; Sahng Wook Park; Michael S Brown; Joseph L Goldstein Journal: Proc Natl Acad Sci U S A Date: 2003-09-25 Impact factor: 11.205
Authors: Ronald G Victor; Robert W Haley; DuWayne L Willett; Ronald M Peshock; Patrice C Vaeth; David Leonard; Mujeeb Basit; Richard S Cooper; Vincent G Iannacchione; Wendy A Visscher; Jennifer M Staab; Helen H Hobbs Journal: Am J Cardiol Date: 2004-06-15 Impact factor: 2.778
Authors: Shelby Sullivan; Elisa Fabbrini; Jay D Horton; Kevin Korenblat; Bruce W Patterson; Samuel Klein Journal: Transl Res Date: 2011-07-19 Impact factor: 7.012
Authors: Q Feng; W Q Wei; C P Chung; R T Levinson; L Bastarache; J C Denny; C M Stein Journal: Pharmacogenomics J Date: 2016-02-23 Impact factor: 3.550
Authors: Lili Wang; Jeff Smith; Camilo Breton; Peter Clark; Jia Zhang; Lei Ying; Yan Che; Janel Lape; Peter Bell; Roberto Calcedo; Elizabeth L Buza; Alexei Saveliev; Victor V Bartsevich; Zhenning He; John White; Mingyao Li; Derek Jantz; James M Wilson Journal: Nat Biotechnol Date: 2018-07-09 Impact factor: 54.908
Authors: Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder Journal: J Lipid Res Date: 2014-04-28 Impact factor: 5.922
Authors: Kevin Fitzgerald; Maria Frank-Kamenetsky; Svetlana Shulga-Morskaya; Abigail Liebow; Brian R Bettencourt; Jessica E Sutherland; Renta M Hutabarat; Valerie A Clausen; Verena Karsten; Jeffrey Cehelsky; Saraswathy V Nochur; Victor Kotelianski; Jay Horton; Timothy Mant; Joseph Chiesa; James Ritter; Malathy Munisamy; Akshay K Vaishnaw; Jared A Gollob; Amy Simon Journal: Lancet Date: 2013-10-03 Impact factor: 79.321
Authors: Susan G Lakoski; Fang Xu; Gloria L Vega; Scott M Grundy; Manisha Chandalia; Chun Lam; Robert S Lowe; Michael E Stepanavage; Thomas A Musliner; Jonathan C Cohen; Helen H Hobbs Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958